A House investigative panel plans to hold a new hearing to grill the drug maker behind a 400 percent price hike for the life-saving allergy drug EpiPen.
The House Oversight Committee’s Sept. 21 hearing will include testimony from Mylan CEO Heather Bresch on the high price tag of $600 for EpiPens. She later lowered the price for some patients after public outcry.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.